Oncology Clinical Trials in Duluth, MN
As of August 2026, 38 paid clinical trials are recruiting for Oncology in Duluth, Minnesota. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
38 clinical trials for Oncology
·Clear filters·Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
E-Mindfulness Approaches for Living After Breast Cancer
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Integrated Cancer Repository for Cancer Research
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Top Research Study Locations in Duluth
Researchers run research studies in Duluth, MN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Essentia Health Cancer Center | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma | 73 |
| Miller-Dwan Hospital | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma | 31 |
| Essentia Health Saint Mary's Medical Center | Malignant Digestive System Neoplasm, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 26 |
| Saint Luke's Hospital of Duluth | Anatomic Stage II Breast Cancer AJCC v8, Melanoma, Acute Lymphoblastic Leukemia | 7 |
| Essentia Health | ASCVD, Cardiovascular Diseases, Chronic Kidney Disease(CKD) | 4 |
| Zenith Vision Development Center | Amblyopia | 3 |
| Aspirus Saint Luke's Hospital | Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | 1 |
| Aspirus St. Luke's Clinic - Duluth - Oncology & Hematology | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | 1 |
| Clinical Study Sites | Non-Small Cell Lung Cancer | 1 |
| Essentia Health - Duluth | Lumbar Spinal Stenosis | 1 |
| Essentia Health - Duluth Clinic | Anal Cancer, Bile Duct Cancer, Bladder Cancer | 1 |
| Essentia Health-SMMC | Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | 1 |
| Essentia Institute of Rural Health | Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM) | 1 |
| Great Lakes Hub | Mental Health Issue, Substance Use | 1 |
| Harm Reduction Sisters | Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | 1 |
| Lakewalk Surgery Center | Lumbar Spinal Stenosis | 1 |
| Local Institution - 0054 | Schizophrenia | 1 |
| MNCCTN Essentia Health Duluth | Adenocarcinoma of Lung, Lung Cancer | 1 |
| Massive Bio SYNERGY-AI site | BRCA Gene Rearrangement, Bladder Cancer, Breast Cancer | 1 |
| Saint Marys Medical Center | Cardiovascular Disease | 1 |
| St. Luke'S | Non Small Cell Lung Carcinoma | 1 |
| St. Luke's Hospital | Cancer Harboring BRAF Alterations, HGG, LGG | 1 |
| St. Luke's Hospital of Duluth | Anal Cancer, Bile Duct Cancer, Bladder Cancer | 1 |
| St. Lukes Hospital of Duluth | Chronic Lymphocytic Leukemia (CLL) | 1 |
| St. Mary's Duluth Clinic Regional Heart Center | Heart Failure - NYHA II - IV | 1 |
Active & Upcoming Studies in Duluth (2026)
Recruiting trials in Duluth grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (77 active studies)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · Phase 3 · National Cancer Institute (NCI)
- A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment · Phase 2 · Alliance for Clinical Trials in Oncology
Mental health & behavior (4 active studies)
- Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · Bristol-Myers Squibb
- Gii'Igoshimong: Sitting With Your First Family · Phase 2 · Johns Hopkins Bloomberg School of Public Health
Cardiovascular (3 active studies)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis · Phase 3 · Duke University
- Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure · Boston Scientific Corporation
Diabetes & metabolic (2 active studies)
Vaccines (1 active study)
Common conditions studied in Duluth
- Acute Myeloid Leukemia (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Lung Non-Small Cell Carcinoma (5 active studies)
- Breast Cancer (4 active studies)
- Melanoma (4 active studies)
- Stage IV Lung Cancer AJCC v8 (4 active studies)
Leading research sponsors in Duluth
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- NRG Oncology
- Duke University
Frequently asked questions
How many paid clinical trials are currently recruiting in Duluth?
There are approximately 103 recruiting clinical trials in Duluth, Minnesota listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Duluth pay participants?
Most recruiting trials in Duluth compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Duluth?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Duluth?
The most common conditions under active study in Duluth include Acute Myeloid Leukemia (6), Anatomic Stage II Breast Cancer AJCC v8 (5), Lung Non-Small Cell Carcinoma (5), Breast Cancer (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Duluth?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Duluth on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Duluth?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Duluth?
Recruiting research sites in Duluth include Essentia Health Cancer Center, Miller-Dwan Hospital, Essentia Health Saint Mary's Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Duluth right now?
The largest active categories in Duluth are Cancer & tumors (77), Mental health & behavior (4), Cardiovascular (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.